Reported Q3 2025 net loss of $36.8 million, or $0.97 per share, compared to $25.2 million, or $0.74 per share, in Q3 2024123
Revenue for Q3 2025 was $0.396 million, down from $2.17 million year-over-year12
Estimated adjusted cash, cash equivalents, and investments of ~$525 million as of September 30, 2025, providing runway into 20283
Raised $288.4 million through a public offering, contributing to strong cash position of approximately $555.5 million before certain payments13
Research and development expenses increased due to higher clinical costs, milestones, and headcount for claseprubart development3
Earnings missed analyst estimates:
EPS of -$0.97 vs. consensus -$0.86, revenue below expectations45
Sources:
1. https://www.tipranks.com/news/company-announcements/dianthus-therapeutics-reports-q3-2025-financial-results
2. https://www.marketscreener.com/news/dianthus-therapeutics-inc-reports-earnings-results-for-the-third-quarter-and-nine-months-ended-sep-ce7d5cddde8efe21
3. https://www.globenewswire.com/news-release/2025/11/05/3181899/0/en/Dianthus-Therapeutics-Highlights-Recent-Business-Achievements-and-Reports-Q3-Financial-Results.html
4. https://www.nasdaq.com/articles/dianthus-therapeutics-inc-dnth-reports-q3-loss-lags-revenue-estimates